Skip to content
HowShorted

CAPRICOR THERAPEUTICS, INC. short interest in 2025

In 2025, CAPRICOR THERAPEUTICS, INC.'s disclosed short interest ran from 16.69% of shares outstanding on 15 Jan 2025 to 35.91% on 28 Nov 2025, a change of +19.22 percentage points. The year's high was 35.91% on 28 Nov 2025 and its low 16.69% on 15 Jan 2025, averaging 23.99% across 22 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 11.27 days on 15 Oct 2025. Full history: CAPRICOR THERAPEUTICS, INC..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for CAPRICOR THERAPEUTICS, INC. in 2025

2025 in figures

Start of year
16.69% (15 Jan 2025)
End of year
35.91% (28 Nov 2025)
Change
+19.22 pp
High
35.91% (28 Nov 2025)
Low
16.69% (15 Jan 2025)
Average
23.99%
Highest days to cover
11.27 (15 Oct 2025)
SEC filings marked
8

Every report in 2025

CAPRICOR THERAPEUTICS, INC. short interest in 2025
SettlementShort interestDays to coverFilings since previous
15 Jan 202516.69%8.25
31 Jan 202516.87%10.93
14 Feb 202517.95%8.54
28 Feb 202517.96%6.64
14 Mar 202519.95%5.53
31 Mar 202520.37%5.50results (8-K), 10-K filed
15 Apr 202523.36%8.07
30 Apr 202522.64%7.49
15 May 202530.17%3.39results (8-K), 10-Q filed
30 May 202524.26%5.10
13 Jun 202522.36%4.66
30 Jun 202524.46%2.51
15 Jul 202521.46%2.88
31 Jul 202524.31%4.86
15 Aug 202524.83%7.7210-Q filed, results (8-K)
29 Aug 202525.14%8.51
15 Sep 202526.57%11.16
30 Sep 202525.68%7.18
15 Oct 202526.79%11.27
31 Oct 202528.99%10.85
14 Nov 202530.96%7.9010-Q filed, results (8-K)
28 Nov 202535.91%7.18

See also: CAPRICOR THERAPEUTICS, INC.'s full history · most shorted US stocks of 2025 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.